Cargando…
Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966386/ https://www.ncbi.nlm.nih.gov/pubmed/24655581 http://dx.doi.org/10.3201/eid2004.131063 |
_version_ | 1782308904413167616 |
---|---|
author | Barlow, Russell S. DeBess, Emilio E. Winthrop, Kevin L. Lapidus, Jodi A. Vega, Robert Cieslak, Paul R. |
author_facet | Barlow, Russell S. DeBess, Emilio E. Winthrop, Kevin L. Lapidus, Jodi A. Vega, Robert Cieslak, Paul R. |
author_sort | Barlow, Russell S. |
collection | PubMed |
description | To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility to ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Of 2,153 cases, 2,127 (99%) nontyphoidal Salmonella isolates were obtained from a specific source (e.g., feces, urine, blood, or other normally sterile tissue) and had been tested for drug susceptibility. Among these, 347 (16%) isolates had CIR. The odds of acquiring CIR infection significantly increased each year. Hospitalization was more likely for patients with than without CIR infections. Among patients with isolates that had been tested, we analyzed data from 1,813 (84%) who were interviewed. Travel to eastern or Southeast Asia was associated with increased CIR. Isolates associated with outbreaks were less likely to have CIR. Future surveillance activities should evaluate resistance with respect to international travel. |
format | Online Article Text |
id | pubmed-3966386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-39663862014-04-02 Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 Barlow, Russell S. DeBess, Emilio E. Winthrop, Kevin L. Lapidus, Jodi A. Vega, Robert Cieslak, Paul R. Emerg Infect Dis Research To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility to ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Of 2,153 cases, 2,127 (99%) nontyphoidal Salmonella isolates were obtained from a specific source (e.g., feces, urine, blood, or other normally sterile tissue) and had been tested for drug susceptibility. Among these, 347 (16%) isolates had CIR. The odds of acquiring CIR infection significantly increased each year. Hospitalization was more likely for patients with than without CIR infections. Among patients with isolates that had been tested, we analyzed data from 1,813 (84%) who were interviewed. Travel to eastern or Southeast Asia was associated with increased CIR. Isolates associated with outbreaks were less likely to have CIR. Future surveillance activities should evaluate resistance with respect to international travel. Centers for Disease Control and Prevention 2014-04 /pmc/articles/PMC3966386/ /pubmed/24655581 http://dx.doi.org/10.3201/eid2004.131063 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Barlow, Russell S. DeBess, Emilio E. Winthrop, Kevin L. Lapidus, Jodi A. Vega, Robert Cieslak, Paul R. Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title | Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title_full | Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title_fullStr | Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title_full_unstemmed | Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title_short | Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 |
title_sort | travel-associated antimicrobial drug–resistant nontyphoidal salmonellae, 2004–2009 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966386/ https://www.ncbi.nlm.nih.gov/pubmed/24655581 http://dx.doi.org/10.3201/eid2004.131063 |
work_keys_str_mv | AT barlowrussells travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 AT debessemilioe travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 AT winthropkevinl travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 AT lapidusjodia travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 AT vegarobert travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 AT cieslakpaulr travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009 |